Immunotherapy employs patients' own immune systems to fight cancer, and it has shown itself to be an effective treatment in ...

Programmed death-1 (PD-1) inhibition with pembrolizumab led to durable remission in 31.3% of patients with early acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) relapse after ...

During a live event, Nataliya Mar, MD, discussed systemic therapies such as lenvatinib/pembrolizumab in advanced renal cell ...

New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive ...

The KEYNOTE-905 study is ongoing and will evaluate other endpoints including EFS, OS, and pCR rate for neoadjuvant and adjuvant pembrolizumab vs surgery alone.

New trial results reveal enfortumab vedotin and pembrolizumab significantly improve survival for muscle-invasive bladder ...

The promising trial results may be a breakthrough for cisplatin-ineligible patients with muscle-invasive bladder cancer.

Cylembio is a therapeutic cancer vaccine candidate that targets cells and immune-suppressive cells in the tumor microenvironment through activation and expansion of T cells against IDO1 and/or PD-L1 ...

Sustained benefits seen in overall survival, progression-free survival, objective response rate with combo vs sunitinib.

Pembrolizumab, an anti–programmed death 1 (PD-1) monoclonal antibody, is a cornerstone of first-line standard care for recurrent and metastatic HNSCC. 1,2,7 The addition of pembrolizumab to ...

Conclusions: Pembrolizumab plus next-line chemotherapy in pts with advanced NSCLC who experienced PD after clinical benefit to CPI was associated with prolonged PFS compared with historical controls ...

Pembrolizumab and Severe Hypertriglyceridemia Requiring Apheresis: An Immune-Related Adverse Event The following represents disclosure information provided by authors of this manuscript. All ...